5' Nucleotidase - Pipeline Review, H1 2020
According to the recently published report '5' Nucleotidase – Pipeline Review, H1 2020'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 220.127.116.11) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 18.104.22.168) – 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
The report '5' Nucleotidase – Pipeline Review, H1 2020' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 126.96.36.199) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 16 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma, Triple-Negative Breast Cancer (TNBC), Breast Cancer, Colorectal Cancer, Kidney Cancer (Renal Cell Cancer), Prostate Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook